Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

5.120 USD -0.100 (-1.92%)
Official Closing Price Updated: 5:22 PM EST, Mar 8, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Affimed Ord Shs

< Previous 1 2 3 4 5 6 7 Next >
Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors
From GlobeNewswire News Releases
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From GlobeNewswire News Releases
Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares
From GlobeNewswire News Releases
Affimed Announces Proposed Public Offering of Common Shares
From GlobeNewswire News Releases
Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank
From GlobeNewswire News Releases
Affimed Announces Pipeline and Business Update
From GlobeNewswire News Releases
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Rec
From GlobeNewswire News Releases
Thinking about buying stock in Affimed NV, Kura Oncology, Matinas BioPharma, Uranium Energy, or Senseonics Holdings?
InvestorsObserver issues critical PriceWatch Alerts for AFMD, KURA, MTNB, UEC, and SENS. 
From PR Newswire
Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood
From GlobeNewswire News Releases
Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress
From GlobeNewswire News Releases
Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets
From GlobeNewswire News Releases
New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Natural Killer Cells
From GlobeNewswire News Releases
Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies
From GlobeNewswire News Releases
Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition
From GlobeNewswire News Releases
Affimed to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020
From GlobeNewswire News Releases
Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy
From GlobeNewswire News Releases
Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy
From GlobeNewswire News Releases
Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From GlobeNewswire News Releases
Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13
From GlobeNewswire News Releases
Affimed to Present at Jefferies Virtual Cell Therapy Summit
From GlobeNewswire News Releases
Affimed to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Affimed Reports Second Quarter 2020 Financial Results and Operational Progress
From GlobeNewswire News Releases
Affimed Announces Two New Appointments to Its Supervisory Board
From GlobeNewswire News Releases
Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020
From GlobeNewswire News Releases
Affimed Announces Annual General Meeting of Shareholders
From GlobeNewswire News Releases
Affimed Reports First Quarter 2020 Financial Results and Operational Progress
From GlobeNewswire News Releases
Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed’s ROCK® Platform, at AACR Virtual Annual Meeting II
From GlobeNewswire News Releases
Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Canc
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.